Published in N Engl J Med on April 24, 2013
The medical device excise tax--before it begins? N Engl J Med (2013) 0.92
The medical device excise tax--before it begins? N Engl J Med (2013) 0.92
The medical device excise tax--before it begins? N Engl J Med (2013) 0.90
The patient protection and Affordable Care Act: a primer for hand surgeons. Hand Clin (2014) 0.82
The medical device excise tax--before it begins? N Engl J Med (2013) 0.75
Implications of health reform for the medical technology industry. Health Aff (Millwood) (2010) 3.56
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Rethinking global access to vaccines. BMJ (2008) 3.60
The 21st Century Cures Act--Will It Take Us Back in Time? N Engl J Med (2015) 3.52
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
High-cost generic drugs--implications for patients and policymakers. N Engl J Med (2014) 2.79
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Research ethics. Paying patients for their tissue: the legacy of Henrietta Lacks. Science (2012) 2.10
Origins of medical innovation: the case of coronary artery stents. Circ Cardiovasc Qual Outcomes (2012) 2.08
FDA regulation of mobile health technologies. N Engl J Med (2014) 1.96
Regulation of medical devices in the United States and European Union. N Engl J Med (2012) 1.89
The variability and quality of medication container labels. Arch Intern Med (2007) 1.83
Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med (2011) 1.82
Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm (2010) 1.78
Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med (2014) 1.78
Creating a medical, ethical, and legal framework for complex living kidney donors. Clin J Am Soc Nephrol (2006) 1.74
Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades. Health Aff (Millwood) (2012) 1.50
Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med (2013) 1.45
Pharmaceutical marketing and the new social media. N Engl J Med (2010) 1.43
Postmarket surveillance of medical devices: a comparison of strategies in the US, EU, Japan, and China. PLoS Med (2013) 1.37
Why do the same drugs look different? Pills, trade dress, and public health. N Engl J Med (2011) 1.28
How Medicare could get better prices on prescription drugs. Health Aff (Millwood) (2009) 1.27
How does medical device regulation perform in the United States and the European union? A systematic review. PLoS Med (2012) 1.24
Effect of financial relationships on the behaviors of health care professionals: a review of the evidence. J Law Med Ethics (2012) 1.23
Reputation and precedent in the bevacizumab decision. N Engl J Med (2011) 1.21
The consequences of requesting "dispense as written". Am J Med (2011) 1.16
Health policy basics: the Physician Payment Sunshine Act and the Open Payments program. Ann Intern Med (2014) 1.09
State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood) (2010) 1.08
Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood) (2008) 1.03
Prescription-drug coupons--no such thing as a free lunch. N Engl J Med (2013) 1.00
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 0.99
Assessment of US pathway for approving medical devices for rare conditions. BMJ (2014) 0.98
Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood) (2010) 0.95
Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J Law Med Ethics (2013) 0.95
Progress and Hurdles for Follow-on Biologics. N Engl J Med (2015) 0.95
User fees and beyond--the FDA Safety and Innovation Act of 2012. N Engl J Med (2012) 0.93
Scientific and legal viability of follow-on protein drugs. N Engl J Med (2008) 0.92
Ensuring patient privacy in data sharing for postapproval research. N Engl J Med (2014) 0.90
Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status. JAMA (2012) 0.89
Conflict of interest disclosure in early education of medical students. JAMA (2011) 0.88
Using a drug-safety tool to prevent competition. N Engl J Med (2014) 0.88
Drug development and FDA approval, 1938-2013. N Engl J Med (2014) 0.86
Forbidden and Permitted Statements about Medications--Loosening the Rules. N Engl J Med (2015) 0.86
Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy. Am J Cardiol (2011) 0.85
The role of direct-to-consumer pharmaceutical advertising in patient consumerism. Virtual Mentor (2013) 0.83
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015. Ann Intern Med (2016) 0.82
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2009) 0.82
Physician trainees' interactions with the pharmaceutical industry. J Gen Intern Med (2013) 0.81
Approval of high-risk medical devices in the US: implications for clinical cardiology. Curr Cardiol Rep (2014) 0.81
Drug company gifts to medical students: the hidden curriculum. BMJ (2013) 0.79
Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparency. Health Aff (Millwood) (2014) 0.78
Expanded access to investigational drugs. N Engl J Med (2015) 0.77
Same song, different audience: pharmaceutical promotion targeting non-physician health care providers. PLoS Med (2013) 0.77
Regulating Homeopathic Products - A Century of Dilute Interest. N Engl J Med (2016) 0.77
Medical innovation then and now: perspectives of innovators responsible for transformative drugs. J Law Med Ethics (2014) 0.77
Breakthrough Medical Devices and the 21st Century Cures Act. Ann Intern Med (2016) 0.76
Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care (2014) 0.76
The Watchman saga--closure at last? N Engl J Med (2015) 0.76
Evidence, errors, and ethics. Perspect Biol Med (2014) 0.76
Adalimumab pricing and market exclusivity for biologics. N Engl J Med (2010) 0.75
The 21st Century Cures Act. N Engl J Med (2015) 0.75
The medical device excise tax--before it begins? N Engl J Med (2013) 0.75
The NIH translational research center might trade public risk for private reward. Nat Med (2011) 0.75
Burden of changes in generic pill appearance. Ann Intern Med (2014) 0.75
Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey. J Grad Med Educ (2015) 0.75
High-cost generic drugs--implications for patients and policymakers. N Engl J Med (2015) 0.75
Questions about the 10 x '20 Initiative. Clin Infect Dis (2010) 0.75
A cross-national comparison of 17 countries' insulin glargine drug labels. Pharmacoepidemiol Drug Saf (2014) 0.75
Patterns and predictors of generic narrow therapeutic index drug use among older adults. J Am Geriatr Soc (2013) 0.75
Expert review of drug patent applications: improving health in the developing world. Health Aff (Millwood) (2009) 0.75
Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. Hastings Cent Rep (2017) 0.75
Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era? Yale J Health Policy Law Ethics (2015) 0.75
Ethical issues in new drug prescribing. J Bioeth Inq (2011) 0.75
Balancing access and innovation: India's Supreme Court rules on imatinib. JAMA (2013) 0.75
The ethics of intellectual property rights in an era of globalization. J Law Med Ethics (2013) 0.75
A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges? Food Drug Law J (2015) 0.75